Patents by Inventor Brenda K. Mann
Brenda K. Mann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240122850Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.Type: ApplicationFiled: June 6, 2023Publication date: April 18, 2024Inventors: Marina Lee Gerton, Brenda K. Mann
-
Patent number: 11911479Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.Type: GrantFiled: February 1, 2022Date of Patent: February 27, 2024Inventor: Brenda K. Mann
-
Patent number: 11701324Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.Type: GrantFiled: February 19, 2021Date of Patent: July 18, 2023Inventors: Marina Lee Gerton, Brenda K. Mann
-
Publication number: 20220287961Abstract: The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.Type: ApplicationFiled: May 27, 2022Publication date: September 15, 2022Inventors: Brenda K. MANN, Hee-Kyoung LEE
-
Publication number: 20220273800Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.Type: ApplicationFiled: May 29, 2018Publication date: September 1, 2022Inventor: Brenda K. Mann
-
Patent number: 11419941Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.Type: GrantFiled: May 29, 2018Date of Patent: August 23, 2022Inventor: Brenda K. Mann
-
Patent number: 11376214Abstract: The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.Type: GrantFiled: April 30, 2020Date of Patent: July 5, 2022Assignee: KIORA PHARMACEUTICALS, INC.Inventors: Brenda K. Mann, Hee-Kyoung Lee
-
Publication number: 20220152209Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.Type: ApplicationFiled: February 1, 2022Publication date: May 19, 2022Inventor: Brenda K. Mann
-
Publication number: 20210299039Abstract: The disclosure provides an ocular drug delivery system that includes a contact lens and a drug delivery portion, which may include a compound having the formula X—(CH2)n-Z, wherein X is a photocrosslinkable group. Advantageously, the drug delivery portion may aid in loading a high concentration of a negatively-charged therapeutic agent into the ocular drug delivery system. Additionally, the disclosed ocular drug delivery system may aid in controlled delivery of the negatively-charged therapeutic agent to the eye of a patient over a period of about 4 to about 24 hours.Type: ApplicationFiled: March 23, 2021Publication date: September 30, 2021Applicant: EyeGate Pharmaceuticals, Inc.Inventors: Brenda K. Mann, Darren Stirland, Michael Manzo, Heather Sheardown, Talena Rambarran, Lina Liu
-
Publication number: 20210290527Abstract: The present disclosure relates to compositions and methods for treating ocular conditions or diseases with low or poorly water-soluble therapeutics incorporated into a hydrogel. In particular, the disclosure relates to non-blurring, therapeutic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.Type: ApplicationFiled: March 22, 2021Publication date: September 23, 2021Applicant: EyeGate Pharmaceuticals, Inc.Inventors: Brenda K. Mann, Hee-Kyoung Lee
-
Publication number: 20210169797Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.Type: ApplicationFiled: February 19, 2021Publication date: June 10, 2021Inventors: Marina Lee Gerton, Brenda K. Mann
-
Patent number: 10959945Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.Type: GrantFiled: December 27, 2018Date of Patent: March 30, 2021Inventors: Marina Lee Gerton, Brenda K. Mann
-
Publication number: 20200345634Abstract: The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.Type: ApplicationFiled: April 30, 2020Publication date: November 5, 2020Applicant: EyeGate Pharmaceuticals, Inc.Inventors: Brenda K. Mann, Hee-Kyoung Lee
-
Publication number: 20190365902Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.Type: ApplicationFiled: May 29, 2018Publication date: December 5, 2019Inventor: Brenda K. Mann
-
Publication number: 20190290582Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.Type: ApplicationFiled: December 27, 2018Publication date: September 26, 2019Inventors: Marina Lee Gerton, Brenda K. Mann
-
Patent number: 7635592Abstract: Matrix-enhancing molecules, such as TGF-?, are conjugated to or immobilized on scaffolds to increase ECM production by cells for tissue engineering, tissue regeneration and wound healing applications. The matrix-enhancing molecule is conjugated to a tether, such as polyethylene glycol (PEG) monoacrylate, for attachment to a tissue engineering or cell growth scaffold. The matrix-enhancing molecule retains activity after attachment to the scaffold, and causes cells growing in or on the scaffold to increase extracellular matrix (ECM) production, without substantially increasing proliferation of the cells, even when the scaffold additionally contains cell adhesion ligands. The increased ECM produced by the cells aids in maintaining the integrity of the scaffold, particularly when the scaffold is degradable, either by hydrolysis or by enzymatic degradation.Type: GrantFiled: August 21, 2001Date of Patent: December 22, 2009Assignee: Rice UniversityInventors: Jennifer L. West, Brenda K. Mann
-
Publication number: 20020106793Abstract: Matrix-enhancing molecules, such as TGF-&bgr;, are conjugated to or immobilized on scaffolds to increase ECM production by cells for tissue engineering, tissue regeneration and wound healing applications. The matrix-enhancing molecule is conjugated to a tether, such as polyethylene glycol (PEG) monoacrylate, for attachment to a tissue engineering or cell growth scaffold. The matrix-enhancing molecule retains activity after attachment to the scaffold, and causes cells growing in or on the scaffold to increase extracellular matrix (ECM) production, without substantially increasing proliferation of the cells, even when the scaffold additionally contains cell adhesion ligands. The increased ECM produced by the cells aids in maintaining the integrity of the scaffold, particularly when the scaffold is degradable, either by hydrolysis or by enzymatic degradation.Type: ApplicationFiled: August 21, 2001Publication date: August 8, 2002Inventors: Jennifer L. West, Brenda K. Mann